|
|
Iranian Heart Journal، جلد ۲۶، شماره ۲، صفحات ۳۹-۴۸
|
|
|
| عنوان فارسی |
|
|
| چکیده فارسی مقاله |
|
|
| کلیدواژه‌های فارسی مقاله |
|
|
| عنوان انگلیسی |
The Efficacy and Safety of Ticagrelor Compared With Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction Scheduled for a Pharmaco-Invasive Reperfusion Strategy |
|
| چکیده انگلیسی مقاله |
Background: ST-segment elevation myocardial infarction (STEMI) is a critical component of acute coronary syndrome and is often managed with a pharmaco-invasive strategy when primary percutaneous coronary intervention (pPCI) is not immediately available. Although ticagrelor has demonstrated superior outcomes in pPCI settings, its efficacy and safety compared with clopidogrel in a pharmaco-invasive approach remain less studied. This study aimed to evaluate the safety and efficacy of ticagrelor compared with clopidogrel in STEMI patients undergoing reperfusion with a pharmaco-invasive strategy. Methods: This randomized controlled trial was conducted among 170 STEMI patients treated with fibrinolytic therapy and scheduled for a pharmaco-invasive strategy. Patients were randomized to receive either ticagrelor (the switch group) or clopidogrel (the no-switch group) in addition to standard therapy. The primary outcomes were major bleeding (safety) and a composite of death, reinfarction, or stroke (efficacy) within 6 months. Results: The study found no significant differences in in-hospital outcomes, including resuscitated cardiac arrest, shock, and major bleeding between the groups. At 6 months, the composite efficacy endpoint occurred in 1.2% of the ticagrelor group compared with 4.7% in the clopidogrel group (P = 0.368). Kaplan-Meier analysis revealed a divergence in event rates beginning in the fifth month, with the ticagrelor group exhibiting a slightly higher event rate by the sixth month (10% vs 9.8%). Conclusions: In STEMI patients treated with a pharmaco-invasive strategy, ticagrelor and clopidogrel demonstrated similar safety profiles. Although the ticagrelor group exhibited a lower incidence of the composite efficacy endpoint, this difference was not statistically significant. (Iranian Heart Journal 2025; 26(2): 39-48) |
|
| کلیدواژه‌های انگلیسی مقاله |
STEMI,Pharmaco-invasive strategy,Ticagrelor,Clopidogrel,randomized controlled trial |
|
| نویسندگان مقاله |
Ahmed Mahmoud Bendary |
Cardiovascular Medicine Department, Faculty of Medicine, Benha University, Benha, Egypt.
Osama Sanad Arafa |
Cardiovascular Medicine Department, Faculty of Medicine, Benha University, Benha, Egypt.
Zainab Gomaa Gamal Awad |
New Cairo Specialized Hospital, Cairo, Egypt.
Yasser Hosny Abd El Rahman |
Cardiovascular Medicine Department, Faculty of Medicine, Benha University, Benha, Egypt.
|
|
| نشانی اینترنتی |
https://journal.iha.org.ir/article_217910_0529b1c568cd1184c1892eb6f9fe100c.pdf |
| فایل مقاله |
فایلی برای مقاله ذخیره نشده است |
| کد مقاله (doi) |
|
| زبان مقاله منتشر شده |
en |
| موضوعات مقاله منتشر شده |
|
| نوع مقاله منتشر شده |
|
|
|
|
برگشت به:
صفحه اول پایگاه |
نسخه مرتبط |
نشریه مرتبط |
فهرست نشریات
|